Skip to content
10-Q

Quarterly Report

TONGLI PHARMACEUTICALS (USA), INC.

0001144204-13-008567

← back to feed
Filed
Feb 14, 2013 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2012 · Feb 10, 2013 14.85M sh
Capex Q3 2012 · Dec 31, 2012 $0
Capex Q3 2012 · Dec 31, 2011 $857
Stockholders Equity Q3 2012 · Dec 31, 2012 $20.46M
Stockholders Equity Q3 2012 · Mar 31, 2012 $18.34M
Current Liabilities Q3 2012 · Dec 31, 2012 $1.18M
Current Liabilities Q3 2012 · Mar 31, 2012 $1.5M
Current Assets Q3 2012 · Dec 31, 2012 $4.35M
Current Assets Q3 2012 · Mar 31, 2012 $9.14M
Total Assets Q3 2012 · Dec 31, 2012 $21.64M
Total Assets Q3 2012 · Mar 31, 2012 $19.84M
Operating Cash Flow Q3 2012 · Dec 31, 2011 −$425.39K
Sga Expense restated Q3 2012 · Dec 31, 2011 $181.91K
Sga Expense restated Q3 2012 · Dec 31, 2011 $1.32M
Net Income Q3 2012 · Dec 31, 2011 $1.26M
Net Income Q3 2012 · Dec 31, 2011 $3.2M
Operating Income Q3 2012 · Dec 31, 2011 $1.73M
Operating Income Q3 2012 · Dec 31, 2011 $4.68M
Gross Profit Q3 2012 · Dec 31, 2011 $2.04M
Gross Profit Q3 2012 · Dec 31, 2011 $6.41M
Cost Of Revenue Q3 2012 · Dec 31, 2011 $2.08M
Cost Of Revenue Q3 2012 · Dec 31, 2011 $7.18M